Inactive Instrument

Aceto Corporation

ACETO Corporation Appoints Vimal Kavuru to its Board of Directors

February 02, 2017 at 08:06 pm

ACETO Corporation announced that it has appointed Vimal Kavuru, 48 years old, to its Board of Directors, effective February 2, 2017. Since 2013, Mr. Kavuru has been the CEO and a founder of Citron Pharma LLC and Lucid Pharma LLC, from which Aceto subsidiary Rising Pharmaceuticals acquired certain generic products and related assets in December 2016. In 2008, Mr. Kavuru founded Gen-Source RX and served as CEO until 2014 when that business was sold to Cardinal Health. Since 2007, Mr. Kavuru has served as a director of Celon Labs Ltd.

Latest news about Aceto Corporation

Actylis and Novo Nordisk Pharmatech Announce a Strategic Partnership for the Distribution of Benzalkonium Chloride in Targeted European Countries	03-25	CI
Actylis Launches A New Cgmp Wfi Generation, Storage, and Distribution System with Additional Iso Class 7 Manufacturing Space	21/09/23	CI
Actylis Opens a 30,000Ft² cGMP Facility to Bolster its Innovative Api Manufacturing Capabilities	27/02/23	CI
Aceto Corporation acquired Talus Mineral Company and Biotron Laboratories, Inc.	01/03/22	CI
Aceto Corporation acquired A & C Bio Buffer Limited.	11/10/21	CI
Aceto Corporation acquired Cascade Chemistry.	01/06/21	CI
Aceto Corporation acquired an unknown majority stake in Finar Ltd.	16/05/21	CI
Aceto Strengthens Self-Manufacturing and Vaccine and Biopharmaceutical Offering with Acquisition of A&C	15/04/21	CI
Aceto Corporation acquired A&C.	14/04/21	CI
Aceto to Expand Bioreagent Offering to Support Growing Customer Demand in Biopharma and Cell Culture Manufacturing	15/03/21	CI
Aceto Corporation acquired IsleChem, LLC.	20/12/20	CI
Aceto Corporation's Equity Buyback announced on December 11, 2009, has expired.	30/05/20	CI
Aceto Corporation completed the acquisition of Syntor Fine Chemicals Limited.	16/04/20	CI
Aceto Corporation agreed to acquire Syntor Fine Chemicals Limited.	05/04/20	CI
Aceto Corporation Went Out of Business	01/10/19	CI
Second Motion for Exclusivity Period Extension Approved For Aceto Corporation	20/09/19	CI
Second Modified Joint Liquidation Plan and Disclosure Statement Approved for Aceto Corporation	18/09/19	CI
Motion for Asset Sale Approved for Aceto Corporation	04/09/19	CI
Motion for Asset Sale Filed by Aceto Corporation	12/08/19	CI
Disclosure Statement Approved on Interim Basis for Aceto Corporation	26/07/19	CI
Aceto Announces Management Changes	20/06/19	CI
Aceto Corporation Announces Executive Changes	18/06/19	CI
First Motion for Exclusivity Period Extension Approved For Aceto Corporation	18/06/19	CI
Joint Liquidation Plan and Disclosure Statement Filed by Aceto Corporation	17/06/19	CI
Aceto Corporation Announces the Termination of William C. Kennally, III as President and Chief Executive Officer of the Company	03/06/19	CI

Chart Aceto Corporation

Duration

Period

More charts

Company Profile

Tri Harbor Holdings Corp., also known as Aceto, is a United States-based virtual manufacturer engaged in supplying specialty materials. The Company is primarily engaged in supplying its materials to life sciences and advanced technology end markets. The Company operates its business operations in nine countries, and distributes over 1,100 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals